Press Release
... about the location and extent of disease. At the same time, this new approach also provides new therapeutic modalities which can improve the still poor prognosis of CRPC-patients in the future. The leading part is played by a protein called Prostate-Specific Membrane Antigen (PSMA). It is found abun ...
... about the location and extent of disease. At the same time, this new approach also provides new therapeutic modalities which can improve the still poor prognosis of CRPC-patients in the future. The leading part is played by a protein called Prostate-Specific Membrane Antigen (PSMA). It is found abun ...
- Wiley Online Library
... during this initial monitoring. Active surveillance must be distinguished from watchful waiting, which for decades has described a policy of observation with the use of palliative treatment for symptomatic progression. Or in other words, to emphasize the differences between these contrasting ...
... during this initial monitoring. Active surveillance must be distinguished from watchful waiting, which for decades has described a policy of observation with the use of palliative treatment for symptomatic progression. Or in other words, to emphasize the differences between these contrasting ...
PSA and Prostate Cancer
... a prostate biopsy — done. Prostate cancer that is felt by rectal exam represents a higher stage than one diagnosed by a biopsy done due to elevated PSA. Many patients who present with prostate cancer that can be felt on rectal exam may have an advanced stage where cure is not an option and palliatio ...
... a prostate biopsy — done. Prostate cancer that is felt by rectal exam represents a higher stage than one diagnosed by a biopsy done due to elevated PSA. Many patients who present with prostate cancer that can be felt on rectal exam may have an advanced stage where cure is not an option and palliatio ...
BIRM, AN ANDEAN PLANT EXTRACT, DOWN REGULATES
... potential chemopreventive potential of BIRM against prostate cancer. DISCUSSION: Total androgen deprivation is a common treatment option for patients with advanced prostate cancer (2). Although most patients initially respond to this therapy, the disease quickly progresses to an androgen-refractory ...
... potential chemopreventive potential of BIRM against prostate cancer. DISCUSSION: Total androgen deprivation is a common treatment option for patients with advanced prostate cancer (2). Although most patients initially respond to this therapy, the disease quickly progresses to an androgen-refractory ...
File
... ❏ bony metastasis to axial skeleton is very common (osteoblastic) ❏ soft tissue metastasis is less common with liver, lung and adrenal metastases occurring most frequently ❏ obstructive and irritative symptoms uncommon without spread ❏ suspect with prostatism, incontinence +/- back pain ❏ hard irreg ...
... ❏ bony metastasis to axial skeleton is very common (osteoblastic) ❏ soft tissue metastasis is less common with liver, lung and adrenal metastases occurring most frequently ❏ obstructive and irritative symptoms uncommon without spread ❏ suspect with prostatism, incontinence +/- back pain ❏ hard irreg ...
Abstract Number
... General Hospital, Harvard Medical School, Boston, MA Background: High-risk, localized prostate cancer (PCa) patients have a relatively poor prognosis. We hypothesized that the addition of adjuvant docetaxel and prednisone to long-term (24 month) AS and radiation therapy (RT) would improve overall su ...
... General Hospital, Harvard Medical School, Boston, MA Background: High-risk, localized prostate cancer (PCa) patients have a relatively poor prognosis. We hypothesized that the addition of adjuvant docetaxel and prednisone to long-term (24 month) AS and radiation therapy (RT) would improve overall su ...
Prostate Cancer Screening Guideline Summary
... in Table 1,* consider repeating the PSA test within one month. If the repeat PSA value still exceeds the age specific thresholds, referral to Urology is recommended. (*Note: Normal variation of PSA values of ~20% have been demonstrated in some studies.) ...
... in Table 1,* consider repeating the PSA test within one month. If the repeat PSA value still exceeds the age specific thresholds, referral to Urology is recommended. (*Note: Normal variation of PSA values of ~20% have been demonstrated in some studies.) ...
Guideline Statement 1
... certainty that the harms of an intervention equal or outweigh the benefits. Mass screening is also a lucrative business. “It is difficult to get a man to understand something, when his salary depends on his not understanding it”. Although the Task Force statement is more pointed than those of other ...
... certainty that the harms of an intervention equal or outweigh the benefits. Mass screening is also a lucrative business. “It is difficult to get a man to understand something, when his salary depends on his not understanding it”. Although the Task Force statement is more pointed than those of other ...
Prostate Cancer Patient Symposium
... life after prostate cancer treatment. Managing advanced prostate cancer. Provide an update on new treatment options for advanced disease. Using the internet to gather information. Understanding possible prostate cancer prevention options. ...
... life after prostate cancer treatment. Managing advanced prostate cancer. Provide an update on new treatment options for advanced disease. Using the internet to gather information. Understanding possible prostate cancer prevention options. ...
Prostate Specific Antigen (PSA)
... PSA is also used in the pre-operative staging of prostate cancer. Concentrations of PSA increase linearly from the lowest clinical stage, Stage T1, to the most advanced cancer, Stage T4. PSA results are also used to determine the effectiveness of treatment. After radical prostatectomy (surgical remo ...
... PSA is also used in the pre-operative staging of prostate cancer. Concentrations of PSA increase linearly from the lowest clinical stage, Stage T1, to the most advanced cancer, Stage T4. PSA results are also used to determine the effectiveness of treatment. After radical prostatectomy (surgical remo ...
Continuous versus intermittent androgen deprivation
... Professor of Medicine Cleveland Clinic Lerner College of Medicine ...
... Professor of Medicine Cleveland Clinic Lerner College of Medicine ...
we are gathered here today as family and friends to honor the 90th
... encourage the citizens of the Village of Lakeview to increase the importance of prostate screenings. ...
... encourage the citizens of the Village of Lakeview to increase the importance of prostate screenings. ...
Mens sexual health
... All candidates for radical treatment should have the opportunity to discuss their treatment options with a surgical oncologist and a clinical oncologist. Offer adjuvant hormonal therapy for a minimum of 2 years to men receiving radiotherapy who have a Gleason score of ≥ 8. ...
... All candidates for radical treatment should have the opportunity to discuss their treatment options with a surgical oncologist and a clinical oncologist. Offer adjuvant hormonal therapy for a minimum of 2 years to men receiving radiotherapy who have a Gleason score of ≥ 8. ...
MANAGEMENT OF EARLY PROSTATE CANCER
... cause of cancer death in men in the United States. Prostate cancer is predominantly a disease of the elderly man, with more than 75% of new prostate cancers being diagnosed in men older than 65 years. ...
... cause of cancer death in men in the United States. Prostate cancer is predominantly a disease of the elderly man, with more than 75% of new prostate cancers being diagnosed in men older than 65 years. ...
Sophiris Bio Presents Topsalysin Data from Phase 2a Proof
... Sophiris Bio Inc. is a biopharmaceutical company developing topsalysin (PRX302), a first-in-class treatment for patients with urological diseases. Topsalysin is in Phase 2 clinical development for the focal treatment of localized prostate cancer as well as Phase 3 clinical development for the treatm ...
... Sophiris Bio Inc. is a biopharmaceutical company developing topsalysin (PRX302), a first-in-class treatment for patients with urological diseases. Topsalysin is in Phase 2 clinical development for the focal treatment of localized prostate cancer as well as Phase 3 clinical development for the treatm ...
a new potential biomarker for prostate cancer diagnosis
... with the development, invasion, metastasis and prognosis of various cancers including prostate cancer. Circulating miRNAs may be useful for early diagnosis as well as to predict the clinical outcome and the treatment response. The aim of this study was to investigate the hypothesis that changes in c ...
... with the development, invasion, metastasis and prognosis of various cancers including prostate cancer. Circulating miRNAs may be useful for early diagnosis as well as to predict the clinical outcome and the treatment response. The aim of this study was to investigate the hypothesis that changes in c ...
Testicular cancer overview
... patients will ultimately progress • Some patients will not have an initial response to therapy • Are there predictive or surrogate biomarkers to guide treatment decisions? ...
... patients will ultimately progress • Some patients will not have an initial response to therapy • Are there predictive or surrogate biomarkers to guide treatment decisions? ...
Initial Results of a Phase III Randomized Study of High Dose 3D
... Based on information to date, reporting of primary findings is indicated. Important secondary endpoint and adverse event information is also reported. Materials/Methods: Men with prostate cancer, clinical stage T1b-T2b and Gleason Score (GS) 2-6 and PSA ≥ 10 and <20 or clinical stage T1b-T2b and GS ...
... Based on information to date, reporting of primary findings is indicated. Important secondary endpoint and adverse event information is also reported. Materials/Methods: Men with prostate cancer, clinical stage T1b-T2b and Gleason Score (GS) 2-6 and PSA ≥ 10 and <20 or clinical stage T1b-T2b and GS ...
Prostate Specific Antigen
... PSA is also used in the pre-operative staging of prostate cancer. Concentrations of PSA increase linearly from the lowest clinical stage, Stage T1, to the most advanced cancer, Stage T4. PSA results are also used to determine the effectiveness of treatment. After radical prostatectomy (surgical remo ...
... PSA is also used in the pre-operative staging of prostate cancer. Concentrations of PSA increase linearly from the lowest clinical stage, Stage T1, to the most advanced cancer, Stage T4. PSA results are also used to determine the effectiveness of treatment. After radical prostatectomy (surgical remo ...